Tenet Healthcare (NYSE:THC) Stock Acquired Rep. Jonathan L. Jackson

Core Viewpoint - Representative Jonathan L. Jackson has recently invested in Tenet Healthcare Corporation, indicating confidence in the company's stock performance and potential growth [2][3]. Company Performance - Tenet Healthcare's stock opened at $201.46, with a market capitalization of $17.71 billion, a price-to-earnings ratio of 13.81, and a PEG ratio of 0.86 [3]. - The stock has a 50-day moving average of $202.22 and a 200-day moving average of $189.81, indicating a stable price trend [3]. - The company reported earnings per share (EPS) of $3.70 for the last quarter, surpassing the consensus estimate of $3.33 by $0.37, with quarterly revenue of $5.29 billion, slightly above the expected $5.26 billion [4]. - Year-over-year revenue growth was 3.2%, and the company has set its FY 2025 EPS guidance between 15.930 and 16.26 [4]. Analyst Ratings and Price Targets - Wall Street Zen upgraded Tenet Healthcare from a "buy" to a "strong-buy" rating, while Weiss Ratings upgraded it from "hold (c+)" to "buy (b-)" [5]. - Goldman Sachs initiated coverage with a "buy" rating and a price target of $224.00, while Guggenheim raised their target from $238.00 to $257.00 [5]. - Cantor Fitzgerald increased their price objective from $190.00 to $245.00, and the average rating for the stock is currently "Moderate Buy" with a consensus price target of $233.81 [5]. Insider Transactions - Director Tammy Romo sold 15,099 shares at an average price of $200.81, totaling approximately $3.03 million, representing a 24.21% decrease in her position [8]. - Insider R. Scott Ramsey sold 13,322 shares at an average price of $205.11, amounting to about $2.73 million [8]. - Over the last quarter, insiders sold a total of 45,500 shares valued at approximately $9.25 million, with insiders currently owning 0.81% of the stock [8]. Institutional Holdings - Institutional investors own 95.44% of Tenet Healthcare's stock, indicating strong institutional confidence in the company [9]. - Recent institutional investments include Triumph Capital Management and William B. Walkup & Associates, both acquiring new stakes in the company [9].